Northwestern Mutual Wealth Management Co. Takes $1.58 Million Position in Biogen Inc. $BIIB

Northwestern Mutual Wealth Management Co. purchased a new stake in Biogen Inc. (NASDAQ:BIIB) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,299 shares of the biotechnology company’s stock, valued at approximately $1,577,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Reflection Asset Management acquired a new position in shares of Biogen during the 4th quarter worth approximately $25,000. Bell Investment Advisors Inc acquired a new stake in shares of Biogen in the second quarter valued at approximately $27,000. WFA of San Diego LLC bought a new stake in shares of Biogen in the second quarter valued at approximately $32,000. Root Financial Partners LLC boosted its stake in shares of Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares during the period. Finally, MV Capital Management Inc. acquired a new stake in Biogen during the fourth quarter worth approximately $34,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on BIIB. Wall Street Zen lowered Biogen from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Needham & Company LLC increased their target price on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Evercore started coverage on Biogen in a research report on Friday, May 15th. They issued an “outperform” rating on the stock. Truist Financial raised Biogen from a “hold” rating to a “buy” rating and boosted their price target for the company from $190.00 to $235.00 in a research note on Monday, July 13th. Finally, Barclays upped their price objective on shares of Biogen from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $227.79.

Biogen Stock Up 1.2%

NASDAQ BIIB opened at $220.77 on Wednesday. The business has a fifty day moving average price of $206.42 and a two-hundred day moving average price of $195.12. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 1.26. Biogen Inc. has a fifty-two week low of $131.52 and a fifty-two week high of $222.85. The stock has a market capitalization of $32.62 billion, a PE ratio of 39.07, a PEG ratio of 6.80 and a beta of 0.17.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. During the same quarter last year, the company posted $5.47 EPS. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities analysts expect that Biogen Inc. will post 12.39 earnings per share for the current fiscal year.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: LEQEMBI IQLIK launches in the U.S.: Biogen and Eisai announced that the once-weekly subcutaneous autoinjector is now available to initiate treatment for adults with early Alzheimer’s disease. The option can be administered at home, potentially reducing clinic visits, improving treatment convenience and expanding adoption of LEQEMBI. LEQEMBI IQLIK Autoinjector Available in the U.S.
• Positive Sentiment: Potential commercial benefit: LEQEMBI IQLIK offers flexibility between intravenous and subcutaneous dosing for both initiation and maintenance therapy. Easier administration could lower barriers for patients and caregivers and support longer-term revenue growth from Biogen’s Alzheimer’s partnership with Eisai. The drug has demonstrated a 27% slowing of cognitive decline versus placebo in the pivotal study, although Biogen shares commercialization with Eisai.
• Positive Sentiment: Fundamental and institutional support: Biogen’s latest reported quarter included adjusted EPS of $3.60 and revenue of $2.74 billion, both ahead of expectations. Recent data also indicate more institutional investors increased positions than reduced them, while several analysts maintain Buy or Outperform ratings and a median price target around $225.
• Neutral Sentiment: Short-interest report appears unreliable: The data lists zero shares sold short both before and after the reporting period, making the stated “large increase” and NaN percentage mathematically meaningless. It provides no credible evidence of a short squeeze or materially changed investor positioning.
• Negative Sentiment: Bearish valuation commentary: A recent analysis titled “3 Reasons to Sell BIIB” argues that the shares’ roughly 14.4% six-month gain has largely followed the broader market, raising questions about additional upside and relative attractiveness. The article’s bearish view could limit enthusiasm after the recent rally. 3 Reasons to Sell BIIB and 1 Stock to Buy Instead
• Negative Sentiment: LEQEMBI safety risks remain: The treatment carries a boxed warning for amyloid-related imaging abnormalities, including potentially serious brain swelling and hemorrhage. These risks, along with required MRI monitoring and higher ARIA incidence among ApoE ε4 homozygotes, could constrain uptake and increase implementation costs.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.